✦ LIBER ✦

PMS46 Cost-Utility Analysis of Certolizumab Pegol versus Alternative Tumor Necrosis Factor-Inhibitors, for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Spain

✍ Scribed by R. Villoro; A. Hidalgo; B. Ferro; P. Talavera

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS45 Cost-Utility and Budget Impact Ana

✍ N. Maniadakis; D. Boumpas; G. Kourlaba; P. Christou; I. Anargiros; E. Smets; O P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PMS28 COST-UTILITY ANALYSIS OF TUMOR NEC

✍ CM Nguyen; M Mendes; M Bounthavong; M Christopher; AP Morreale 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

BL1 COST-EFFECTIVENESS, VALUE OF INFORMA

✍ EJ Soini; T Hallinen; M Taiha; V Honkanen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PMS34 AN EXPLORATORY EVALUATION OF THE C

✍ S Yunger; B Mistry 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB